192 related articles for article (PubMed ID: 28476040)
21. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
[TBL] [Abstract][Full Text] [Related]
22. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y
Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828
[TBL] [Abstract][Full Text] [Related]
23. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
24. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
Landmann H; Proia DA; He S; Ogawa LS; Kramer F; Beißbarth T; Grade M; Gaedcke J; Ghadimi M; Moll U; Dobbelstein M
Cell Death Dis; 2014 Sep; 5(9):e1411. PubMed ID: 25210794
[TBL] [Abstract][Full Text] [Related]
25. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
26. HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression.
Liu H; Lu Z; Shi X; Liu L; Zhang P; Golemis EA; Tu Z
J Biol Chem; 2021 Aug; 297(2):100996. PubMed ID: 34302809
[TBL] [Abstract][Full Text] [Related]
27. Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition.
Gomez-Casal R; Epperly MW; Wang H; Proia DA; Greenberger JS; Levina V
Oncotarget; 2015 Dec; 6(42):44306-22. PubMed ID: 26517240
[TBL] [Abstract][Full Text] [Related]
28. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in
Chatterjee S; Huang EH; Christie I; Kurland BF; Burns TF
Mol Cancer Ther; 2017 May; 16(5):793-804. PubMed ID: 28167505
[TBL] [Abstract][Full Text] [Related]
29. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
30. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
31. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.
Youssef ME; Cavalu S; Hasan AM; Yahya G; Abd-Eldayem MA; Saber S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902446
[TBL] [Abstract][Full Text] [Related]
32. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
Choi HK; Lee K
Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
[TBL] [Abstract][Full Text] [Related]
33. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
[TBL] [Abstract][Full Text] [Related]
34. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
[TBL] [Abstract][Full Text] [Related]
35. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
[TBL] [Abstract][Full Text] [Related]
36. Ganetespib radiosensitization for liver cancer therapy.
Chettiar ST; Malek R; Annadanam A; Nugent KM; Kato Y; Wang H; Cades JA; Taparra K; Belcaid Z; Ballew M; Manmiller S; Proia D; Lim M; Anders RA; Herman JM; Tran PT
Cancer Biol Ther; 2016 Apr; 17(4):457-66. PubMed ID: 26980196
[TBL] [Abstract][Full Text] [Related]
37. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.
Proia DA; Foley KP; Korbut T; Sang J; Smith D; Bates RC; Liu Y; Rosenberg AF; Zhou D; Koya K; Barsoum J; Blackman RK
PLoS One; 2011 Apr; 6(4):e18552. PubMed ID: 21533169
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
Int J Cancer; 2019 Sep; 145(6):1529-1537. PubMed ID: 30801702
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
Breinig M; Mayer P; Harjung A; Goeppert B; Malz M; Penzel R; Neumann O; Hartmann A; Dienemann H; Giaccone G; Schirmacher P; Kern MA; Chiosis G; Rieker RJ
Clin Cancer Res; 2011 Apr; 17(8):2237-49. PubMed ID: 21372220
[TBL] [Abstract][Full Text] [Related]
40. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
